The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1
- 15 December 1990
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 40 (12) , 2683-2687
- https://doi.org/10.1016/0006-2952(90)90587-b
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb–IIIa complex in rat and in manBiochemical Pharmacology, 1990
- Effect of PCR 4099 on ADP-induced calcium movements and phosphatidic acid production in rat plateletsBiochemical Pharmacology, 1988
- Effect of ticlopidine on platelet intracellular calcium mobilizationThrombosis Research, 1988
- Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADPThrombosis Research, 1987
- TiclopidineDrugs, 1987
- Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.Journal of Clinical Investigation, 1985
- Ni‐mediated inhibition of human platelet adenylate cyclase by thrombinEuropean Journal of Biochemistry, 1984
- Cytoplasmic free Ca2+ in human platelets: Ca2+ thresholds and Ca‐independent activation for shape‐change and secretionFEBS Letters, 1982